Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company, announced on Tuesday that it has treated its first patient in part two, the randomised stage, of the phase two BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) with a prior sinus surgery.
The product is designed to deliver six months of continuous anti-inflammatory medication at a controlled rate to the sinonasal passages for CRS patients that continue to need treatment despite prior surgical treatment.
The Phase 2 BEACON trial, a parallel-group study, is to assess safety, tolerability, and pharmacokinetics of LYR-220 (7500-microg MF) matrix, over a 24-week period, in symptomatic adult CRS patients who have had a prior bilateral sinus surgery.
During the randomised Part two stage, one design of the product will be compared to control in around 40 patients. The firm expects to complete enrolment for the full Phase two BEACON trial around the end of 2022.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007